Attention Deficit/Hyperactivity Disorder
Conditions
Interventions
investigational material(s)
Generic name etc : Intuniv Tablets (Guanfacine)
INN of investigational material : guanfacine
Therapeutic category code : 117 Psychotropic agents
Dosage and Administration f
Body weight 17 kg <= to <25 kg : 1 mg-1 mg-2 mg, 25 kg <= to <34 kg : 1 mg-2 mg-3 mg, 34 kg <= to <38 kg : 1 mg-2 mg-4 mg, 38 kg <= to <42 kg : 1 mg-3 mg-4 mg, 42 kg <= to <50 kg : 1 mg-3 mg-5 mg, 50
Sponsors
SHIONOGI & CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with attention deficit/hyperactivity disorder (AD/HD) who fulfill the following criteria will be included in the surveillance. Inclusion criteria 1. Subject has no experience of using Study Drug. 2. Subject is from 6 to under 18 years old (as of starting Study Drug administration). (The investigation will be continued when the subjects become over the age of 18 during the observation period.) 3. Subject has no experience of using other AD/HD drugs for 14 days before starting Study Drug administration (except the date of starting Study Drug administration). 4. Subject has the teacher's and physician's evaluation score by the ADHD RS-IV before starting Study Drug administration.
Exclusion criteria
Exclusion criteria: -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety efficacy Safety, Efficacy ADHD RS-IV | — |
Secondary
| Measure | Time frame |
|---|---|
| other - | — |
Countries
Japan
Contacts
Public ContactContact for Clinical Trial Information
Takeda Pharmaceutical Company Limited
Outcome results
None listed